Q1 2025 Ligand Pharmaceuticals Inc Earnings Call Transcript

May 8, 2025 / 12:30 PM GMT

Release Date Price: €89 (-0.56%)

Transcript 10-Q8-K

Key Points

Positve

Ligand Pharmaceuticals Inc (LGND) reported a 46% increase in top-line revenue and an 11% growth in adjusted EPS for Q1 2025.
The company has a strong cash position with over $200 million in cash and investments, and no debt, providing financial flexibility.
Ligand Pharmaceuticals Inc (LGND) has a diversified portfolio with more than 90 assets across various stages of clinical development and therapeutic areas.
The company executed a strategic transaction to merge its subsidiary Pelthos Therapeutics with Channel Therapeutics, securing substantial financial backing.
Ligand Pharmaceuticals Inc (LGND) is experiencing strong demand for royalty financing, which is expected to be a positive tailwind for the company in 2025.

Negative

The current biopharmaceutical financing environment is challenging, with fewer IPOs and difficulties in private fundraising.
There is significant short-term disruption due to restructuring and personnel changes in government institutions, including the FDA.
Ligand Pharmaceuticals Inc (LGND) reported a GAAP net loss of $42.5 million for the quarter, primarily due to a one-time R&D charge.
The company faces competitive pressures, as seen with Amgen's Kyprolis, which reported a 14% year-over-year decline in sales.
The potential impact of legislative and geopolitical developments, such as tariffs on pharmaceutical products, remains uncertain.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LGND.OQ - Ligand Pharmaceuticals Inc
Q1 2025 Ligand Pharmaceuticals Inc Earnings Call
May 08, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by. My name is Kate and I will be your conference operator today. At this time, I would like to welcome everyone to the li land first quarter 2025 earnings. All lines have been placed on you to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press start, followed with the number one on your telephone keypad. If you would like to withdraw your question, press one again.

Thank you. I would now like to turn the call over to Melanie Herman, executive director of investor relations. Please go ahead.

--------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.